araag2/HINT huggingface dataset:
Clinical trial NCT00109408 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: methotrexate, tocilizumab [roactemra/actemra]
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients at least 18 years of age with active RA for at least 3 months;

          -  patients of reproductive potential must be using reliable methods of contraception.

        Exclusion Criteria:

          -  major surgery (including joint surgery) within 8 weeks before entering study or
             planned major surgery within 6 months after entering study;

          -  treatment with methotrexate (MTX) within 6 months of entering study;

          -  patients who have stopped previous MTX treatment due to toxicity or lack of response;

          -  women who are pregnant or breast-feeding.
Clinical trial NCT01240382 (phase 3, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: 3% de-089 ophthalmic solution, 0.1% sodium hyaluronate ophthalmic solution
SMILES: CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)C(O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@H](O)[C@H]1O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Those who show:

               -  Keratoconjunctival disorder confirmed with vital dye staining

               -  Abnormal Schirmer score results

        Exclusion Criteria:

          -  Eye disease that needs therapy other than that for dry eye

          -  Those who need to wear contact lenses during the clinical study
Clinical trial NCT01630746 (phase 3, status: completed)
Conditions: erosive esophagitis
ICD codes: B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: tak-438, tak-438
SMILES: CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1, CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1
Eligibility criteria:

        Inclusion Criteria:

          1. The participant has been treated with standard-dose or higher-than-standard-dose PPI
             until immediately before the start of the Observation Phase.

          2. Outpatient (in principle)

          3. At the endoscopy scheduled for the Observation Phase (Visit 2), the participant must
             have endoscopically confirmed reflux esophagitis of Grade A to D, as defined by the LA
             classification grading system, which remains insufficiently controlled with
             standard-dose or higher-than-standard-dose PPI therapy.

          4. The participant showed good compliance to the study medication in the Observation
             Phase (compliance rate 80% or more).

        Exclusion Criteria:

          1. Participants with an esophagus-related complication (eosinophilic esophagitis,
             esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis,
             etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or
             physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with
             Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or
             Barrett's esophagus are allowed to be included.

          2. Participants who have received surgery or treatment affecting gastroesophageal reflux
             (cardioplasty, dilation of esophageal stenosis [excluding Schatzki's ring], etc.), or
             who have a history of surgery of stomach or duodenum (excluding removal of benign
             polyp under endoscopy)

          3. Participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer
             (mucosal defect with white coating) at the start of the Observation Phase (Visit 1) or
             at endoscopy during the Observation Phase (Visit 2) . However, participants with
             gastric or duodenal erosions are allowed to be included.

          4. Participants with a previous or current history of Zollinger-Ellison syndrome, or
             other gastric acid hypersecretion disorders.
Clinical trial NCT00450216 (phase 3, status: completed)
Conditions: ulcer
ICD codes: K63.3, N48.5, H16.003, H16.013, H16.023, H16.043, H16.053
Drugs: ibuprofen/famotidine, ibuprofen
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Expected to require daily administration of an NSAID for at least the coming six
             months for conditions such as osteoarthritis, rheumatoid arthritis, chronic low back
             pain, chronic regional pain syndrome, and chronic soft tissue pain.

          -  Did not use a NSAID within the 30 days prior to study entry

        Exclusion Criteria:

          -  History of erosive esophagitis

          -  History of any of the following serious gastrointestinal complications:

               -  perforation of ulcers,

               -  gastric outlet obstruction due to ulcers, or

               -  gastrointestinal bleeding.

          -  Active cardiac, renal, and/or hepatic disease

          -  Current Helicobacter pylori (H. pylori) infection

          -  Use of an acid suppressant agent, misoprostol, or more than 325 mg/day of aspirin
             within the 14 days prior to study entry.

          -  Uncontrolled diabetes

          -  Uncontrolled hypertension

          -  Positive pregnancy test at screening

          -  Positive test at Screening for human immunodeficiency virus (HIV), hepatitis B, or
             hepatitis C.

          -  Currently participating, or participation within 30 days prior to study entry, in an
             investigational drug study

        Please note that there are other additional criteria. The study center will determine if
        patients meet all of the criteria.
Clinical trial NCT00103922 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: cilomilast
SMILES: [H][C@@]1(CC[C@](CC1)(C#N)C1=CC(OC2CCCC2)=C(OC)C=C1)C(O)=O
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of COPD and a history of cigarette smoking.

        Exclusion criteria:

          -  Significant heart or lung disease not associated with COPD.

          -  Significant stomach or intestinal disease.
Clinical trial NCT00108849 (phase 3, status: completed)
Conditions: menopause, postmenopausal vaginal atrophy
ICD codes: E28.310, E28.319
Drugs: estradiol, 10 mcg
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women whose last menstruation was at least two years previously
Clinical trial NCT00478231 (phase 3, status: completed)
Conditions: acquired immunodeficiency syndrome, hiv infection
ICD codes: D84.9, D81.9, D83.9, D84.821, B20, D82.2, D84.822, Z21
Drugs: maraviroc
SMILES: CC(C)C1=NN=C(C)N1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with limited or no approved treatment options available to them due to
             resistance or intolerance;

          -  Subjects must be failing to achieve adequate virologic suppression on their current
             regimen and have HIV-1 RNA ≥ 1000 copies/ml, at screening.

          -  Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay.

        Exclusion Criteria:

          -  Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trials or having
             previously discontinued Maraviroc in trials

          -  Potentially life threatening (Grade 4) laboratory abnormality or medical condition
             (according to the Division of AIDS table for grading severity of adult adverse
             experiences) still under investigation unless a diagnosis has been established and
             felt not to affect risk/benefit assessment or eventual interpretation of safety
             results, based on discussion between the investigator and Pfizer.
Clinical trial NCT00267969 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: ustekinumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with plaque-type psoriasis diagnosed at least 6 months prior and covering at
             least 10% of total body surface areas

          -  Have psoriasis area-and-severity index score of >=12

          -  Patients who are considered by treating dermatologist to be a candidate for
             phototherapy or systemic treatment of psoriasis

          -  Have no history of latent or active TB

        Exclusion Criteria:

          -  Currently have nonplaque forms of psoriasis or drug-induced psoriasis

          -  Have any therapeutic agent targeted at reducing IL-12 or IL-23

          -  Have had a BCG vaccination within the previous 12 months

          -  Have a history of chronic or recurrent infectious disease or who have or have had a
             serious infection requiring hospitalization or intravenous antibiotics within the
             previous 2 months

          -  Have or ever have had a nontuberculous mycobacterial infection or opportunistic
             infection

          -  Patients known to be infected with human immunodeficiency virus, hepatitis B, or
             hepatitis C

          -  Have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic,
             hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral,
             or psychiatric disease

          -  Patients with a malignancy or who have a history of malignancy (with the exception of
             certain skin cancers and pre-invasive cervical cancer)
Clinical trial NCT00598156 (phase 3, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: erlotinib (tarceva), bevacizumab (avastin)
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. Adenocarcinoma of the colon or rectum.

          2. Age > 18.

          3. Measurable disease according to RECIST criteria.

          4. Expected survival more than three months.

          5. Adequate bone marrow, liver and kidney function.

          6. INR < 1.5 times upper limit.

          7. Adequate contraception for fertile patients.

          8. Signed written informed consent.

        Exclusion Criteria:

          1. Earlier chemotherapy for metastatic colorectal cancer.

          2. Adjuvant treatment within 6 months.

          3. Surgery or significant trauma within 28 days prior to study entry.

          4. Planned radiotherapy against target lesions.

          5. CNS metastases.

          6. Prior malignancy within 5 years except ca in situ of cervix and basal cell carcinoma.

          7. Bleeding diathesis

          8. Uncontrolled hypertension.

          9. Significant cardiovascular disease.

         10. Treatment with anticoagulant drugs.

         11. Participation in other clinical trial.

         12. Pregnant or lactating.
Clinical trial NCT00403767 (phase 3, status: completed)
Conditions: atrial fibrillation, stroke, embolism
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, G46.4, G46.3, Z82.3, I27.82, I76, O88.02, O88.82, T79.0XXS, T79.1XXS, O03.2
Drugs: rivaroxaban, warfarin, matching placebo for rivaroxaban arm (warfarin placebo), matching placebo for warfarin arm (rivaroxaban placebo)
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, S1SSSSSSS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have documented atrial fibrillation on 2 separate occasions within 6
             months before screening

          -  History of a prior stroke, transient ischemic attack or non-neurologic systemic
             embolism believed to be cardiac in origin, or at least two of the following risk
             factors: heart failure, hypertension, age 75 years or greater, diabetes mellitus

        Exclusion Criteria:

          -  Significant mitral stenosis

          -  Transient atrial fibrillation caused by a reversible disorder

          -  Active internal bleeding

          -  Severe disabling stroke

          -  History of intracranial bleeding

          -  Hemorrhagic disorders
Clinical trial NCT01360021 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: symbicort, symbicort, budesonide
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female 12 years and above

          -  Clinical diagnosis of asthma according to the American Thoracic Society definition at
             least 6 months

          -  Pre-bronchodilator FEV1 ≥ 45% and ≤ 85% of predicted normal

          -  Patients with reversible airway obstruction

          -  Documented daily use of inhaled corticosteroids for ≥ 3 months

        Exclusion Criteria:

          -  History of life-threatening asthma, defined for this protocol as an asthma episode
             that required intubation and/or was associated with hypercapnea, respiratory arrest or
             hypoxic seizures during the 2 years prior to Visit 2

          -  Hospitalized during previous 6 months for asthma

          -  Required emergency treatment more than once during previous 6 months for an
             asthma-related condition

          -  Intake of oral, rectal or parenteral glucocorticosteroid within 30 days of enrolment

          -  Respiratory infection affecting the asthma within 30 days
Clinical trial NCT01663233 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: lcz696, amlodipine, placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Patients must give written informed consent and have a diagnosis of hypertension:

        Untreated patients must have an msSBP ≥ 150 mmHg and < 180 mmHg at both Visit 1 and Visit
        101. Pre-treated patients must have an msSBP ≥ 145 mmHg and < 180 mmHg after wash out at
        Visit 101. All patients must have an office msSBP ≥ 145 mmHg and < 180 mmHg at the
        completion of the 4-week run-in epoch (at the randomization visit (Visit 201).

        Patients must successfully complete ABPM and pass technical requirements at Visit 201.

        Exclusion Criteria:

        Malignant or severe hypertension (grade 3 of WHO classification; msDBP ≥110 mmHg and/or
        msSBP ≥ 180 mmHg).

        History of angioedema, drug-related or otherwise. History or evidence of a secondary form
        of hypertension. Transient ischemic cerebral attack (TIA) during the 12 months prior to
        Visit 1 or any history of stroke.

        History of myocardial infarction, coronary bypass surgery or PCI during the 12 months prior
        to Visit 1

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00083434 (phase 3, status: terminated)
Conditions: anemia, cancer
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    this study was stopped because of an inadequate rate of enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Body weight >/= 99lbs

          -  ECOG 0-2

          -  Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal
             therapy or immunotherapy

          -  Screening hemoglobin level of </= 11.0 g/dL for men or </= 10.0 for women

        Exclusion Criteria:

          -  History of or concurrent second malignancy

          -  Evidence of primary or metastatic malignancy involving the Central Nervous System
Clinical trial NCT00193882 (phase 3, status: completed)
Conditions: esophagus cancer
ICD codes: D13.0, C15.9, C15.3, C15.4, C15.5, C15.8, Z85.01
Drugs: cisplatin, 5-fluorouracil
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Biopsy proven Carcinoma of the oesophagus.

          -  Not a candidate for radical/curative treatment due to the advanced nature of the
             disease, presence of metastases, or intercurrent illness. (It should be noted that,
             patients with mediastinal nodes and no more distant disease maybe suitable for radical
             treatment).

          -  Symptomatic patients with dysphagia scores of ≥ 1 i.e. able to eat only some solids
             (see Mellow Scale appendix 1)

          -  Performance status ECOG ≤ 2

          -  Patients must begin treatment within 2 weeks of randomization.

          -  Patient is at least 18 years old.

          -  Adequate haematological function to undergo chemotherapy. Peripheral blood -
             Neutrophils > 1.5 x 10^9/L - Platelets > 100 x 10^9/L

          -  Adequate renal function, Creatinine - Calculated clearance ≥ 50 ml/min

          -  Patients capable of childbearing are using adequate contraception.

          -  Written informed consent of patient.

        Exclusion Criteria:

          -  Previous mega-voltage external beam Radiotherapy or brachy-therapy delivered to the
             region of the chest.

          -  Synchronous active malignancies.

          -  Pregnant or lactating patients.

          -  Patients unfit for any treatment component.

          -  Tracheo-oesophageal fistula.

          -  Stents in situ.

          -  Previous chemotherapy for Oesophageal Cancer

          -  CT scan of thorax and abdomen more than 8 weeks prior to randomization

          -  Full Blood Count, Biochemistry (including creatinine) and creatinine clearance more
             than 2 weeks prior to randomization
Clinical trial NCT00449150 (phase 3, status: terminated)
Conditions: benign prostatic hypertrophy
ICD codes: J35.3, J35.1, J35.2, N28.81, N62, N85.2, J34.3
Drugs: cetrorelix 78 mg + 78 mg, cetrorelix 78 mg + 52 mg, placebo
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CC1=CC=CS1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    trial did not meet primary efficacy endpoint for double blind phase.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Benign Prostatic Hyperplasia, based on medical history

          -  Voiding symptoms

        Exclusion Criteria:

          -  Urgent need for prostate surgery or prior surgical treatment of the prostate or
             bladder

          -  Major organ dysfunction

          -  Eczema (atopic dermatitis) treated during the last 6 months

          -  Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or
             botulinum toxin type a (Botox) within the last 6 months prior randomization or with α
             blockers or saw palmetto within the last 6 weeks prior to randomization

          -  Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus
             or documented neurologic disorder, urethral stricture disease or history of pelvic
             radiation therapy

          -  History of acute obstructive, infectious, or neurological disorders of the
             genitourinary tract within the last 3 months
Clinical trial NCT00156065 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: haloperidol, asenapine, asenapine
SMILES: OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1, OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Completed the short-term 041023 trial (NCT00156104)

          -  Continued to meet all demographic and procedural inclusion criteria of the short-term
             trial upon entry into this long-term extension trial

          -  Sign a written informed consent for the 041513 trial.

          -  Demonstrated an acceptable degree of compliance with trial medication in the
             short-term trials in the opinion of the investigator

        Exclusion Criteria:

          -  CGI-S (Clinical Global Impressions of Severity of Illness) score of greater than or
             equal to 6 (severely psychotic)

          -  Occurrence(s) of AEs (adverse events) or other clinically significant findings that
             would prohibit their continuation

          -  Met any of exclusion criteria regarding medical/psychiatric status listed in the
             041023 short-term trial

          -  Met exclusion criteria for medication status in short-term trials except for
             antidepressants and mood stabilizers.
Clinical trial NCT00553475 (phase 3, status: completed)
Conditions: diabetic neuropathy, painful
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: placebo, pregabalin, pregabalin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Visual Analogue Scale (VAS) of pain is higher than 40 mm.

          -  Diagnosis of type 1 or 2 diabetes mellitus for at least 1 year

        Exclusion Criteria:

          -  Malignancy within the past 2 years.

          -  Neurologic disorders unrelated to diabetic neuropathy that may confuse the assessment
             of neuropathy pain